Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (CATX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
catx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Perspective Therapeutics, Inc. (CATX) measures how much investors pay for each dollar of the company's trailing earnings. CATX's current PE ratio of N/A is calculated by dividing its stock price of $2.96 by its TTM earnings per share of -$1.07.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Perspective Therapeutics, Inc.You CATX | $229M | N/A | — | -$1.07 |
 Anteris Technologies Global Corp. AVR | $352M | N/A | — | -$3.99 |
 Electromed, Inc. ELMD | $306M | 24.32x | — | $0.90 |
 Solana Company HSDT | $79M | N/A | — | -$1.85 |
 Invivyd, Inc. IVVD | $137M | N/A | — | -$0.30 |
 MaxCyte, Inc. MXCT | $127M | N/A | — | -$0.42 |
 Nano-X Imaging Ltd. NNOX | $137M | N/A | — | -$1.16 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.40 | — | |
2024-12-31 FY2024 | — | $-1.23 | — | |
2023-12-31 FY2023 | — | $-0.85 | — | |
2022-12-31 FY2022 | — | $-0.27 | — | |
2022-06-30 FY2022 | — | $-0.13 | — | |
2021-06-30 FY2021 | — | $-0.06 | — | |
2020-06-30 FY2020 | — | $-0.05 | — | |
2019-06-30 FY2019 | — | $-0.07 | — | |
2018-06-30 FY2018 | — | $-0.12 | — | |
2017-06-30 FY2017 | — | $-0.11 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Perspective Therapeutics, Inc. (CATX) measures how much investors pay for each dollar of the company's trailing earnings. CATX's current PE ratio of N/A is calculated by dividing its stock price of $2.96 by its TTM earnings per share of -$1.07.
Frequently asked questions
CATX pe ratio · 6 questionsCATX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.96 and TTM EPS of -$1.07. Data sourced from Financial Modeling Prep via CATX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Perspective Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08